Trial Profile
A Multicenter, Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Quetmolimab (Primary) ; Quetmolimab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 08 Oct 2014 New trial record